Aptose Biosciences Announces Exclusive License Agreement for Dual BET/Kinase Targeting Program With OHM Oncology Mar 07, 2018 7:00am EST
Aptose Biosciences Files New Preliminary Base Shelf Prospectus to Replace Expired Base Prospectus Feb 07, 2018 4:01pm EST
FDA Grants Orphan Drug Designation to Aptose Biosciences for CG’806 in Acute Myeloid Leukemia Dec 26, 2017 7:30am EST
Aptose Presents New Preclinical Data on CG’806 pan-FLT3/pan-BTK Inhibitor at ASH 59th Annual Meeting Dec 11, 2017 4:04pm EST
Aptose To Release Third Quarter Ended September 30, 2017 Financial Results and Hold Conference Call on November 14, 2017 Nov 07, 2017 8:00am EST
